Microbot Medical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
1.2%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.28next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly105KTarget: Sequential growth exceeding prior quarter
Number of Active Commercial Accounts QuarterlyTarget: Double the Limited Market Release footprint
Net Loss Quarterly-3.7MTarget: Narrowing operating losses through commercial scale
Watch Items
- CE Mark Certification for the European UnionTrigger: Completion targeted by the end of 2026Action: Monitor regulatory submissions and clinical data reviews with European notified bodies.
- Federal Supply Schedule Listing via Lovell Government ServicesTrigger: Expected activation in Q3 2026Action: Verify listing on GSA Advantage, ECAT, and DAPA procurement platforms to access over 2,000 government facilities.
- Commercial Adoption in IsraelTrigger: AMAR marketing clearance granted in May 2026Action: Track distribution agreements and initial commercial sales in the Israeli market.
Research as of 20 Jun 2026